Search results
Added:
1 month ago
ACC 2026 — Drs Karim Al-Azizi (Baylor Scott & White The Heart Hospital, Plano) and Babar Basir (Henry Ford Hospital, US) deliver a short, front-line interventional view of the STEMI Door-to-Unload (STEMI-DTU) trial (NCT03000270), making this an efficient 5-minute update for cardiologists and cath lab teams.STEMI-DTU randomised haemodynamically stable patients aged 18–85 years with a first acute…
View more
PCI Strategies for Calcified Lesions: Systematic Review
Added:
5 months ago
Systematic Review
Added:
1 month ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
8 months ago
Source:
TCT Conference 2025 Programme Guide
Late-breaking clinical trials and science sessions have been announced for Transcatheter Cardiovascular Therapeutics 2025 conference.The conference is set to take place from 25th to 28th October 2025 at the Moscone Center in San Francisco, CA.Access the full programme here.Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetSunday 26th October, 11:00am – 12:28pm (PDT)One…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) requires a careful balance between reducing ischaemic events and minimising bleeding risk. The HOST-BR trial was designed to evaluate the ideal DAPT duration in patients stratified by their bleeding risk.¹This open-label, multicentre, randomised clinical trial enrolled 4,897 patients who…
View more
Laser Focus: Clinical Insights From the Front Line
Video Series
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed 12 Hot-Line trial sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30thAugust to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View from the…
View more
Added:
8 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
6 months ago
TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of…
View more
Added:
8 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more